AMGEN INC
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
AMGN$465.230.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
DEFINED TERMS AND PRODUCTSii
Defined Terms and Products
Defined terms
We use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related, as well as names of other companies, which are provided below.
| Term | Description |
|---|---|
| 2017 Tax Act | Tax Cuts and Jobs Act of 2017 |
| 340B Program | Federal 340B Drug Pricing Program |
| AOCI | accumulated other comprehensive income (loss) |
| AstraZeneca | AstraZeneca plc |
| BeOne | BeOne Medicines Ltd. (formerly BeiGene, Ltd.) |
| BLA | Biologics License Application |
| CMS | Centers for Medicare & Medicaid Services |
| EMA | European Medicines Agency |
| EPS | earnings per share |
| EU | European Union |
| FDA | U.S. Food and Drug Administration |
| Fitch | Fitch Ratings, Inc. |
| G7 | Group of Seven (Canada, France, Germany, Italy, Japan, the United Kingdom and the United States) |
| GAAP | U.S. generally accepted accounting principles |
| HHS | U.S. Department of Health and Human Services |
| Horizon | Horizon Therapeutics plc |
| IPR&D | in-process research and development |
| IRA | Inflation Reduction Act of 2022 |
| IRS | Internal Revenue Service |
| Later-Stage Clinical Programs | R&D expenses incurred in or related to phase 2 and phase 3 clinical programs intended to result in registration of a new product or a new indication for an existing product primarily in the United States or the EU |
| Marketed Product Support | R&D expenses incurred in support of the Company’s marketed products that are authorized to be sold primarily in the United States or the EU. Includes clinical trials designed to gather information on product safety (certain of which may be required by regulatory authorities) and their product characteristics after regulatory approval has been obtained, as well as the costs of obtaining regulatory approval of a product in a new market after approval in either the United States or the EU has been obtained |
| MD&A | management’s discussion and analysis |
| MFN | Most-Favored-Nations |
| MFN EO | Most-Favored-Nations Prescription Drug Pricing Executive Order |
| Moody’s | Moody’s Investors Service, Inc. |
| Neumora | Neumora Therapeutics, Inc. |
| OBBBA | The One Big Beautiful Bill Act |
| OECD | Organisation for Economic Co-operation and Development |
| PBM | pharmacy benefit manager |
| PDAB | Prescription Drug Affordability Board |
| R&D | research and development |
| RANKL | receptor activator of nuclear factor kappa-B ligand |
| RAR | Revenue Agent Report |
| Research and Early Pipeline | R&D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development |
ii
| Term | Description |
|---|---|
| ROW | rest of world |
| S&P | Standard & Poor’s Financial Services LLC |
| SEC | U.S. Securities and Exchange Commission |
| SG&A | selling, general and administrative |
| SOFR | Secured Overnight Financing Rate |
| U.S. Treasury | U.S. Department of the Treasury |
| UTB | unrecognized tax benefit |
iii
Products
The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are provided below.
| Term | Description |
|---|---|
| ACTIMMUNE | ACTIMMUNE® (interferon gamma-1b) |
| Aimovig | Aimovig® (erenumab-aooe) |
| AMJEVITA/AMGEVITA | AMJEVITA® (adalimumab-atto)/AMGEVITA™ (adalimumab) |
| Aranesp | Aranesp® (darbepoetin alfa) |
| AVSOLA | AVSOLA® (infliximab-axxq) |
| BKEMV/BEKEMV | BKEMV™ (eculizumab-aeeb)/BEKEMV™ (eculizumab) |
| BLINCYTO | BLINCYTO® (blinatumomab) |
| BUPHENYL | BUPHENYL® (sodium phenylbutyrate) |
| Corlanor | Corlanor® (ivabradine) |
| ENBREL | Enbrel® (etanercept) |
| EPOGEN | EPOGEN® (epoetin alfa) |
| EVENITY | EVENITY® (romosozumab-aqqg) |
| IMDELLTRA/IMDYLLTRA | IMDELLTRA® (tarlatamab-dlle)/IMDYLLTRA™ (tarlatamab) |
| IMLYGIC | IMLYGIC® (talimogene laherparepvec) |
| KANJINTI | KANJINTI® (trastuzumab-anns) |
| KRYSTEXXA | KRYSTEXXA® (pegloticase) |
| KYPROLIS | KYPROLIS® (carfilzomib) |
| LUMAKRAS/LUMYKRAS | LUMAKRAS®/LUMYKRAS™ (sotorasib) |
| MariTide | Maridebart cafraglutide (MariTide™) |
| MVASI | MVASI® (bevacizumab-awwb) |
| Neulasta | Neulasta® (pegfilgrastim) |
| NEUPOGEN | NEUPOGEN® (filgrastim) |
| Nplate | Nplate® (romiplostim) |
| Otezla | Otezla® (apremilast) |
| Parsabiv | Parsabiv® (etelcalcetide) |
| PAVBLU | PAVBLU® (aflibercept-ayyh) |
| PENNSAID | PENNSAID® (diclofenac sodium topical solution) 2% |
| PROCYSBI | PROCYSBI® (cysteamine bitartrate) |
| Prolia | Prolia® (denosumab) |
| QUINSAIR | QUINSAIR® (levofloxacin) |
| RAVICTI | RAVICTI® (glycerol phenylbutyrate) |
| RAYOS | RAYOS® (prednisone) |
| Repatha | Repatha® (evolocumab) |
| RIABNI | RIABNI® (rituximab-arrx) |
| Sensipar/Mimpara | Sensipar®/Mimpara™ (cinacalcet) |
| TAVNEOS | TAVNEOS® (avacopan) |
| TEPEZZA | TEPEZZA® (teprotumumab-trbw) |
| TEZSPIRE | TEZSPIRE® (tezepelumab-ekko) |
| UPLIZNA | UPLIZNA® (inebilizumab-cdon) |
| Vectibix | Vectibix® (panitumumab) |
| WEZLANA/WEZENLA | WEZLANA™ (ustekinumab-auub)/WEZENLA™ (ustekinumab) |
| XGEVA | XGEVA® (denosumab) |
iv
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.